Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Queensland Health
Cipla
AstraZeneca
Daiichi Sankyo
Colorcon

Generated: September 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,125,149

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,125,149 protect, and when does it expire?

Patent 10,125,149 protects ZERBAXA and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 10,125,149
Title:Synthesis of cephalosporin compounds
Abstract: Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising a palladium-catalyzed coupling reaction. Provided herein are methods for the synthesis of cephalosporin compounds of formula (I) employing a palladium-catalyzed alkylation reaction, as well as compositions related to the same. In an aspect, provided herein is a method for preparing a compound of formula (II), or a salt thereof, comprising the step of admixing, e.g., reacting, a compound of formula (III), or a salt thereof, with a nucleophile (Nuc) in the presence of reagents comprising: (a) a palladium source; and (b) a palladium-binding ligand, to form a compound of formula (II), or a salt thereof.
Inventor(s): Waller; David (Somerville, MA), Gazda; Gregory (Sudbury, MA), Minden; Zachary (Watsonville, CA), Barton; Lisa (Haverhill, MA), Leigh; Clifton (Windham, NH)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:15/503,907
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 10,125,149

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 10,125,149

PCT Information
PCT FiledAugust 14, 2015PCT Application Number:PCT/US2015/045287
PCT Publication Date:February 18, 2016PCT Publication Number: WO2016/025839

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
US Department of Justice
Merck
Covington
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.